CompletedEUCTR 2020-003760-11

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesSchizophrenia

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Germany · Italy and 3 more locations
Study phase: Phase 3

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 586
Sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Germany, Italy, Norway, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2020-003760-11
Official title: Show the full official title
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Germany · Italy · Norway

2 more locations

Poland
Sweden

Registry details

Historical country statuses

Germany — Completed
Italy — Completed
Norway — Completed
Poland — Completed
Sweden — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim Pharma GmbH & Co. KG, a pharmaceutical company.

Want to explore more studies?

Explore studies